Alterations of dendritic cell subsets and Th1/Th2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 5, 2012, Pages 365-371

  Lang, Feng ^a   Linlin, Ma ^a   Ye, Tian ^a   Yuhai, Zhang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cytokines; Dendritic cells; Recurrence; Subset; Superficial transitional cell carcinoma of the bladder

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER PATIENT; CANCER RECURRENCE; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CIRCULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIXED LYMPHOCYTE REACTION; MONOCYTE; MYELOID DENDRITIC CELL; PHENOTYPE; SUPERFICIAL CANCER; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; TH1 CELLS; TH2 CELLS; URINARY BLADDER NEOPLASMS;

EID: 84866609324     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21532     Document Type: Article

References (35)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:475-477.
2. Akagashi K, Tanda H, Kato S, et al. Recurrence pattern for superficial bladder cancer. Int J Urol 2006;13:686-691.
3. Tomoe H, Masumi S, Atsuko O, et al. A possible mechanism of intravesical BCG therapy for human bladder carcinoma: Involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol Immunother 2009;58:1245-1255.
4. Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J Urol 2006;24(5):565-578.
5. Metts MC, Metts JC, Milito SJ, et al. Bladder cancer: A review of diagnosis and management. J Natl Med Assoc 2000;92:285-294.
6. Agarwal A, Agrawal U, Verma S, et al. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 2010;32(3):348-356.
7. Wang Y, Whittall T, McGowan E, et al. Identification of stimulating and inhibitory epitopes within the heat shock protein 70 molecule that modulate cytokine production and maturation of dendritic cells. J Immunology 2010;174(6):3306-3316.
8. Yilmaz A, Reiss C, Weng A, et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 2006;79:529-538.
9. Ishikawa M, Nishioka M, Hanaki N, et al. Hepatic resection leads to predominance of the T-helper-2 lymphocyte phenotype. Hepatol Res 2004;30(2):96-103.
10. Leonie M, van Duivenvoorde, Wanda G, et al. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J Immunol 2007;179:1506-1515.
11. Novotny AR, Emmanuel K, Ulm K, et al. Blood interleukin 12 as preoperativepredictor of fatalpostoperative sepsis after neoadjuvant radiochemotherapy. Br J Surg 2006;93:1283-1289.
12. Masashi I, Masanori N, Norikazu H, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries. World J Surg Oncol 2009;7(7):1-9.
13. Della Bella S, Gennaro M, Vaeeari M, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003;89:1463-1472.
14. Liyanage UK, Moore TT, Joo H, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
15. Sciarra A, Lichtner M, Autran G, et al. Characterization of circulating blood dendritic cell subsets DC123+ (Lymphoid) and DC11C+ (Myeloid) in prostate adenocarcinoma patients. Prostate 2007;67(9):1-7.
16. Herber DL, Nagaraj S, Djeu JY, et al. Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res 2007;67:5067-5069.
17. Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms, and future therapeutic intervention. Semin Cancer Biol 2006;16(1):3-15.
18. Ma XJ, Pan XL, Lv ZH, et al. Therapeutic influence on circulating and monocyte-derived dendritic cells in laryngeal squamous cell carcinoma patients. Acta Oto-laryngologica 2009;129(1):84-91.
19. Bais AG, Beckmann I, Lindemans J, et al. A shift to peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005;58(10):1096-1100.
20. Lech-Maranda E, Bienvenu J, Michallet AS, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B cell lymphoma. Eur Cytokine Network 2006;17:60-66.
21. O'Garra A, Barrat FJ, Castro AG, et al. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008;223:114-131.
22. Philip A, Tadashi M, Priscilla F, et al. Major hepatectomy induces phenotypic changes in circulating dendritic cells and monocytes. J Clin Immunol 2009;29:568-581.
23. Mimura K, Kono K, Takahashi A, et al. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007;56(6):761-770.
24. Tourkova IL, Yamabe K, Foster B, et al. Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate 2004;59:203-213.
25. Kiertscher SM, Luo J, Dubinett SM, et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164:1269-1276.
26. Satyam A, Singh P, Badjatia N, et al. A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol 2011;29(1):58-65.
27. Suttmann H, Jacobsen M, Reiss K, et al. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 2004;172:1490-1495.
28. Kaempfer R, Gerez L, Farbstein H, et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996;14(6):1778-1786.
29. + T cells in patients at the post-acute phase of stroke. Clin Exp Immunol 2008;152(3):456-463.
30. + T cells. Cancer Res 2007;67(23):11428-11437.
31. Sharma A, Rajappa M, Saxena A, et al. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer 2007;17:879-885.
32. Li C, Huang Q, Kung H. Cytokine and immuno-gene therapy for solid tumors. Cell Mol Immunol 2005;2:81-91.
33. Tsai JP, Chen HW, Cheng ML, et al. Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-beta1 and interleukin-6 in the development of in situ tumor immunity. Immunobiology 2005;210(9):661-671.
34. Eldesoky A, Shouma A, Mosaad Y, et al. Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer. Saudi J Gastroenterol 2011;17(3):170-173.
35. Eruslanov E, Neuberger M, Daurkin I, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 2012;130(5):1109-1119.